BMY Wins FDA Nod to Expand Sotyktu Label for Psoriatic Arthritis

FDA approved Bristol Myers' Sotyktu (TYK2 inhibitor) for psoriatic arthritis following strong POETYK study data, adding a new indication. The approval expands Sotyktu's addressable market in immunology and represents a positive revenue catalyst for Bristol Myers, likely to lift the stock by a low-single-digit percentage near term. Monitor real-world uptake, label specifics and payer coverage to assess the timing and magnitude of revenue contribution.

Analysis

FDA approved Bristol Myers' Sotyktu (TYK2 inhibitor) for psoriatic arthritis following strong POETYK study data, adding a new indication. The approval expands Sotyktu's addressable market in immunology and represents a positive revenue catalyst for Bristol Myers, likely to lift the stock by a low-single-digit percentage near term. Monitor real-world uptake, label specifics and payer coverage to assess the timing and magnitude of revenue contribution.